TESTOSTERONE REPLACEMENT THERAPY: ASSESSMENT OF CARDIOVASCULAR RISKS

• DOI: https://doi.org/10.22533/at.ed.1594602426061

• Palavras-chave: Testosterone replacement therapy; Cardiovascular disease; Cardiovascular risk.

• Keywords: Testosterone replacement therapy; Cardiovascular disease; Cardiovascular risk.

• Abstract:

  Objective: Analyze the results of updated 2023 studies to evaluate cardiovascular risks related to testosterone replacement therapy in men, aiming to provide a basis for clinical recommendations. Methodology: Narrative bibliographic review using the PubMed - MEDLINE (Medical Literature Analysis and Retrieval System Online) database. The following search terms were used, along with the Boolean operators "AND" and "OR": Testosterone Replacement Therapy AND Cardiovascular Risk. After applying the inclusion and exclusion criteria, 15 articles were selected for extensive analysis. Review: The results reveal a broad-spectrum view of the topic in question, with the impact of testosterone replacement on the cardiovascular system not being completely evident. In addition to the clinical and physiological benefits of testosterone replacement therapy (TRT), some studies point to a possible increase in cardiovascular adverse events, such as venous thromboembolism, cardiovascular morbidity and mortality, with intramuscular administration being more harmful in this regard, especially in obese men., elderly people, patients with type 2 diabetes, metabolic syndrome and a history of previous cardiovascular disease. Furthermore, there was a tendency to regularly monitor patients on TRT, especially hematocrit levels, to avoid complications such as venous thromboembolism. Final Considerations: The need for clinical and laboratory monitoring of patients is evident, especially in at-risk populations, such as the individualization of therapeutic choice. However, the assessment of the cardiovascular risks associated with TRT in men is still in its infancy due to the limitations of clinical tests, and future studies are needed to better understand the cardiovascular risks of hormone replacement in the target population.